Tania Jain, MBBS, assistant professor at Johns Hopkins University, discusses hematopoietic recovering following treatment with a chimeric antigen receptor (CAR) T-cell therapy in patients with hematologic malignancies.

The most important thing to know, regarding this type of treatment, is that patients can remain cytopenic for a long time following CAR T-cell therapy. In some patients, they can remain cytopenic for months after receiving treatment, says Jain. The need for transfusions and risk for infections needs to be recognized.

Currently, there are no standard guidelines in terms of how long a patient should receive antimicrobial prophylaxis; this remains to be determined so it can prevent infections for a longer period of time in patients.

Conference

® Conference page includes a listing of all conferences covered by 

, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.


CAR T-cell Therapy

 CAR T-cell therapy condition center page is a comprehensive resource for clinical news and expert insights on FDA-approved and investigational CAR T-cell products in hematologic malignancies, specifically acute lymphoblastic leukemia, non-Hodgkin lymphoma, and multiple myeloma. CAR T-cell research in solid tumors is also under exploration. This page features news articles, interviews in written and video format, and podcasts that focus on updates with CAR T-cell therapy and the ongoing research with this type of treatment. 

Transplantation and Cellular Therapy Meetings

Tania Jain, MBBS, discusses hematopoietic recovering following treatment with a chimeric antigen receptor T-cell therapy in patients with hematologic malignancies.

Dr. Jain on Hematopoietic Recovery Following CAR T-Cell Therapy